NCT01473940View on ClinicalTrials.gov

Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 11, 2012

Primary Completion Date

October 16, 2014

Study Completion Date

May 6, 2018

Conditions
Duct Cell Adenocarcinoma of the PancreasRecurrent Pancreatic CancerStage III Pancreatic CancerStage IV Pancreatic Cancer
Interventions
BIOLOGICAL

ipilimumab

Given IV

DRUG

gemcitabine hydrochloride

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

60611

Northwestern University, Chicago

All Listed Sponsors
collaborator

Robert H. Lurie Cancer Center

OTHER

lead

Northwestern University

OTHER

NCT01473940 - Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery | Biotech Hunter | Biotech Hunter